Glycotope Presents Approved GlycoExpress-Technology at BIO-Europe 2010


Berlin, Germany, November 12, 2010 / b3c newswire / - Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress™ technology of novel human cell lines during the upcoming BIO-Europe in Munich. With two of its glycooptimized antibodies produced by GlycoExpress™ and already undergoing clinical trials, four European regulatory authorities approved GlycoExpress™ for production of biotherapeutics. This strongly validates this innovative technology for future development and production of therapeutic proteins. The preclinically observed advantages of glycooptimized biotherapeutics are expected to result in a clear clinical superiority. All glycooptimized products are produced in Glycotope´s own GMP facility in Heidelberg (Glycotope Biotechnology GmbH).



About GlycoExpress™

GlycoExpress™ is based on a tool box of glycoengineered human cell lines for glycooptimization and high yield production of glycooptimized biotherapeutics, such as antibodies. The antibody’s fully human glycosylation is optimized to yield a largely improved anti-tumor ADCC activity, bioavailability and contains no non-human immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. Glycooptimization with GlycoExpress™ is not limited to antibodies but suitable for the majority of therapeutically relevant proteins. The technology platform is available for cooperation partners via service & license agreements.


About Glycotope GmbH -

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant carbohydrate structures known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress™, one of the company’s proprietary technologies, allows making existing and new biopharmaceutical drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development from lead discovery, preclinical development, GMP production down to the clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins.



Glycotope GmbH
Dr. Franzpeter Bracht
Robert-Roessle-Str. 10
13125 BERLIN


Tel.: +49-30-9489-2600
Fax: +49-30-9489-2609

eMail: This email address is being protected from spambots. You need JavaScript enabled to view it.


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.